ES2509117T3 - Composición farmacéutica oral que contiene dabigatran etexilato - Google Patents

Composición farmacéutica oral que contiene dabigatran etexilato Download PDF

Info

Publication number
ES2509117T3
ES2509117T3 ES11704996.5T ES11704996T ES2509117T3 ES 2509117 T3 ES2509117 T3 ES 2509117T3 ES 11704996 T ES11704996 T ES 11704996T ES 2509117 T3 ES2509117 T3 ES 2509117T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
oral pharmaceutical
composition containing
dabigatran etexilate
containing dabigatran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11704996.5T
Other languages
English (en)
Inventor
Sandra Brueck
Jana Paetz
Martin Koeberle
Jutta Strohmeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Application granted granted Critical
Publication of ES2509117T3 publication Critical patent/ES2509117T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica oral que comprende dabigatran etexilato o una sal farmacéuticamente aceptable del mismo, y un excipiente ácido inorgánico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES11704996.5T 2010-03-01 2011-02-28 Composición farmacéutica oral que contiene dabigatran etexilato Active ES2509117T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10155059 2010-03-01
EP10155059 2010-03-01
PCT/EP2011/052919 WO2011107427A1 (en) 2010-03-01 2011-02-28 Dabigatran etexilate-containing oral pharmaceutical composition

Publications (1)

Publication Number Publication Date
ES2509117T3 true ES2509117T3 (es) 2014-10-17

Family

ID=43982233

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11704996.5T Active ES2509117T3 (es) 2010-03-01 2011-02-28 Composición farmacéutica oral que contiene dabigatran etexilato

Country Status (13)

Country Link
US (1) US20130052262A1 (es)
EP (1) EP2542224B1 (es)
JP (1) JP5801826B2 (es)
CA (1) CA2791561A1 (es)
CY (1) CY1115556T1 (es)
DK (1) DK2542224T3 (es)
EA (1) EA201201202A1 (es)
ES (1) ES2509117T3 (es)
IL (1) IL221742A (es)
PL (1) PL2542224T3 (es)
PT (1) PT2542224E (es)
SI (1) SI2542224T1 (es)
WO (1) WO2011107427A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
ITMI20110445A1 (it) * 2011-03-22 2012-09-23 Lo Li Pharma Srl Formulazione farmaceutica comprendente inositolo.
ES2895918T3 (es) * 2012-02-21 2022-02-23 Towa Pharmaceutical Europe S L Composiciones farmacéuticas orales de dabigatrán etexilato
CN103304539A (zh) * 2012-03-07 2013-09-18 天津药物研究院 达比加群酯苹果酸盐及其制备方法和应用
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
IN2013CH05441A (es) * 2013-11-26 2015-05-29 Aurobindo Pharma Ltd
WO2015145462A1 (en) 2014-03-26 2015-10-01 Cadila Healthcare Limited Pharmaceutical compositions of dabigatran
CN105919962B (zh) * 2015-12-18 2019-01-18 重庆两江药物研发中心有限公司 一种达比加群酯片剂及其制备方法
TR201617984A2 (tr) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
CN106491553A (zh) * 2016-12-09 2017-03-15 吉林省博大伟业制药有限公司 一种甲磺酸达比加群酯的新合成工艺
JP2019014712A (ja) * 2017-07-03 2019-01-31 エルメッド エーザイ株式会社 安定なダビガトラン製剤
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
JP2021014411A (ja) * 2019-07-10 2021-02-12 日医工株式会社 安定なダビガトランエテキシラート製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
KR101005716B1 (ko) 2002-03-07 2011-01-05 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20040029774A1 (en) * 2002-08-06 2004-02-12 Aly Gamay Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies
GB0230034D0 (en) * 2002-12-23 2003-01-29 Biochemie Gmbh Organic compounds
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
AR062057A1 (es) * 2006-07-17 2008-10-15 Boehringer Ingelheim Int Uso de los inhibidores directos de la trombina
IL197129A (en) * 2006-08-25 2014-08-31 Boehringer Ingelheim Int Controlled release system and method for production
WO2008043759A1 (en) * 2006-10-10 2008-04-17 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
US8821928B2 (en) * 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
BRPI0915942A2 (pt) * 2008-07-14 2019-04-09 Boehringer Ingelheim International Gmbh método para produção de compostos medicinais contendo dabigatrana
US20110301201A1 (en) * 2008-08-19 2011-12-08 Boehringer Ingelheim Pharmaceuticals Inc. Dabigatran for percutaneous interventional cardiac catheterisation
EP2391893B1 (en) * 2009-02-02 2014-09-03 Boehringer Ingelheim International GmbH Lyophilised dabigatran

Also Published As

Publication number Publication date
SI2542224T1 (sl) 2014-10-30
CY1115556T1 (el) 2017-01-04
DK2542224T3 (da) 2014-10-20
JP5801826B2 (ja) 2015-10-28
EP2542224B1 (en) 2014-08-13
JP2013521244A (ja) 2013-06-10
IL221742A (en) 2015-09-24
EA201201202A1 (ru) 2013-04-30
CA2791561A1 (en) 2011-09-09
PT2542224E (pt) 2014-10-03
WO2011107427A1 (en) 2011-09-09
US20130052262A1 (en) 2013-02-28
EP2542224A1 (en) 2013-01-09
PL2542224T3 (pl) 2014-12-31

Similar Documents

Publication Publication Date Title
ES2509117T3 (es) Composición farmacéutica oral que contiene dabigatran etexilato
ES2631980T3 (es) Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
ES2659758T3 (es) Antagonistas de receptores de 5-HT3
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
ES2487271T3 (es) Formulaciones de dosificación sólidas inhibidoras de DPP-IV
ES2515168T3 (es) Detección y tratamiento de la esquizofrenia
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
GT201600142A (es) Composiciones farmacéuticas que comprenden azd9291
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
HUE053776T2 (hu) Gyógyszerészeti készítmény, amely helyi érzéstelenítõként bupivakaint tartalmaz szájban vagy torokban történõ helyi adagoláshoz
CO2017013293A2 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
CR20120058A (es) Composiciones nuevas de 1 - [2 - (2,4-dimetil-fenilsulfanil)-fenil] piperazina
PA8809601A1 (es) Combinación anti-retroviral
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
AR059357A1 (es) Formulaciones farmaceuticas
EA201170512A1 (ru) Композиция для перорального введения
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
AR088497A1 (es) Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa 4 con atorvastatina
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales